Press Release FeedGet the RSS feed
Menu

Business Wire

Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Business Wire

  • Poster presentation at ESMO Congress 2026 will highlight findings from trial of zoci in combination with atezolizumab with and without carboplatin

  • Data adds to body of evidence supporting zoci as a potential backbone antibody-drug conjugate in first-line combination regimens for ES-SCLC

  • Investor conference call and webcast to discuss data being presented at ESMO and zoci clinical trial plans scheduled for Friday, October 23 at 8:00 a.m. ET / 8:00 p.m. HKT

SHANGHAI & CAMBRIDGE, Mass., September 29, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that global data from a clinical trial evaluating zocilurtatug pelitecan (zoci, formerly ZL-1310) for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) will be shared for the first time at the European Society for Medical Oncology (ESMO) Congress 2026 taking place October 23-27, 2026, in Madrid.

Zoci is a novel, potential first-in-class antibody-drug conjugate (ADC), that targets Delta-like ligand 3 (DLL3), a validated therapeutic target that is overexpressed in SCLC and is generally associated with poor clinical outcomes. The Phase 1b/1c cohort of the global trial is exploring the safety and efficacy of zoci in combination with atezolizumab with or without carboplatin.

"We look forward to sharing results from this trial evaluating zoci as first-line therapy for small cell lung cancer, one of the most aggressive and lethal solid tumors," said Rafael G. Amado, M.D., President, Head of Global Research and Development at Zai Lab. "We continue to be encouraged by zoci's potential best-in-class safety profile, coupled with compelling systemic and intracranial efficacy that support zoci monotherapy as a potential new standard of care in previously treated ES-SCLC, as well as a backbone ADC in first-line combination regimens, including those that reduce the burden of chemotherapy."

ESMO 2026 zoci poster details:

Title: ZL 1310 (DLL3 ADC) plus Atezolizumab ± Carboplatin in extensive-stage small cell lung cancer: Part 1b/1c results from Study ZL 1310-001
Session Title: SCLC
Date/Time: October 26, 2026; 12:00-12:45 CEST
Location: Poster Area – Hall 5
Poster Board Number: 3817P
Abstract Number: 1569

Details regarding the webcast and conference call are as follows:

Date/Time: Friday, October 23, 2026, at 5:00 a.m. PT / 8:00 a.m. ET / 8:00 p.m. HKT
Registration available at:
Webcast presentation (preferred): https://edge.media-server.com/mmc/p/isgbbewu
Dial-in: https://register-conf.media-server.com/register/BI6b181d421fba49dc9171528aeda3974e

  1. SaaSThe Prostate Cancer FoundationProstate Cancer Foundation Expands Radiopharmaceutical Think Tank as Field Enters Pivotal Growth Phase– PCF Think Tank aims to increase adoption of radiopharmaceuticals as major oncology therapeutic platform in prostate cancer treatment and to other tumor types – – New members Orano Med, Telix and Siemens Healthineers join PCF and industry leaders at kickoff meeting at 2026 EANM Annual Congress to address key challenges i
  2. FinanceAlign Technology, Inc.Align Technology Wins Significant Patent Infringement Case Against Angelalign at Unified Patent CourtCompanies: Align TechnologySAN JOSE, Calif. & TEMPE, Ariz., October 17, 2026--Align Technology, Inc. ("Align") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, welcomes the decision of the Unified Patent Court ("UPC") finding that aligner syst
  3. AISyncra and Neumetry Partner to Build AI-Powered Readiness Platform for Teenage Athletes and Their CoachesSmart ring data meets FDA-cleared physiological AI to help coaches see which athletes are ready to compete, and which need rest LAS VEGAS & SAN JOSE, Calif., October 17, 2026--Syncra Labs Inc., maker of the Syncra smart ring, and Neumetry Medical, Inc., developer of an FDA-cleared predictive health pla
  4. HealthcareAIDS Healthcare FoundationAHF Commemorates 40 Years of Global Impact During Annual World AIDS Day Concert Celebration Featuring Ricky MartinLOS ANGELES, October 16, 2026--AIDS Healthcare Foundation (AHF) , the world's largest, non-profit public health organization providing direct HIV/ADS services to over 3.3 million clients across the globe, will celebrate 40 years of impact during its annual World AIDS Day concert commemoration. Continu
  5. Real estateKBRA Assigns Preliminary Ratings to Angel Oak Mortgage Trust 2026-6 (AOMT 2026-6)NEW YORK, October 16, 2026--KBRA assigns preliminary ratings to ten classes of mortgage-backed certificates from Angel Oak Mortgage Trust 2026-6 (AOMT 2026-6), a $250.6 million non-prime RMBS transaction. The underlying collateral, comprised of 381 residential mortgages, and includes a meaningful conce
  6. FinanceUL SolutionsUL Solutions Warns of GFCI and Duplex Wall Outlets Modified by Third Parties to Include Built-in CamerasAfter manufacturing, third parties added built-in cameras to the wall outlets; UL Solutions did not evaluate the modified products and recommends that they be immediately removed from service and discarded. NORTHBROOK, Ill., October 16, 2026--UL Solutions (NYSE: ULS), a global leader in applied safety